3,930 reports of this reaction
3.9% of all DABIGATRAN ETEXILATE MESYLATE reports
#2 most reported adverse reaction
CEREBROVASCULAR ACCIDENT is the #2 most commonly reported adverse reaction for DABIGATRAN ETEXILATE MESYLATE, manufactured by Boehringer Ingelheim Pharmaceuticals Inc.. There are 3,930 FDA adverse event reports linking DABIGATRAN ETEXILATE MESYLATE to CEREBROVASCULAR ACCIDENT. This represents approximately 3.9% of all 101,632 adverse event reports for this drug.
Patients taking DABIGATRAN ETEXILATE MESYLATE who experience cerebrovascular accident should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CEREBROVASCULAR ACCIDENT is moderately reported among DABIGATRAN ETEXILATE MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to cerebrovascular accident, the following adverse reactions have been reported for DABIGATRAN ETEXILATE MESYLATE:
The following drugs have also been linked to cerebrovascular accident in FDA adverse event reports:
CEREBROVASCULAR ACCIDENT has been reported as an adverse event in 3,930 FDA reports for DABIGATRAN ETEXILATE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CEREBROVASCULAR ACCIDENT accounts for approximately 3.9% of all adverse event reports for DABIGATRAN ETEXILATE MESYLATE, making it one of the most commonly reported side effect.
If you experience cerebrovascular accident while taking DABIGATRAN ETEXILATE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.